Get the Stockscreener App
9.39
2.07%
0.19
After Hours:
9.01
-0.38
-4.05%
10 X Genomics Inc stock is traded at $9.39, with a volume of 3.01M.
It is up +2.07% in the last 24 hours and up +16.94% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$9.20
Open:
$9.22
24h Volume:
3.01M
Relative Volume:
0.85
Market Cap:
$1.04B
Revenue:
$631.73M
Net Income/Loss:
$-239.78M
P/E Ratio:
-4.6485
EPS:
-2.02
Net Cash Flow:
$-33.45M
1W Performance:
+7.07%
1M Performance:
+16.94%
6M Performance:
-29.61%
1Y Performance:
-63.31%
1-Day Range:
$8.95
$9.42
1-Week Range:
$8.70
$9.79
52-Week Range:
$6.78
$25.65
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
9.39 | 1.08B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
242.78 | 38.63B | 2.75B | 714.14M | 1.09B | 4.33 |
|
TEM
Tempus Ai Inc
|
65.49 | 10.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
98.23 | 7.82B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
52.56 | 11.11B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
39.34 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker - Stock Titan
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | T - GuruFocus
Analyst Expectations For 10x Genomics's Future - Benzinga
JPMorgan Chase & Co. Cuts 10x Genomics (NASDAQ:TXG) Price Target to $9.00 - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
10x Genomics (NASDAQ:TXG) Shares Gap Up – Time to Buy? - Defense World
10x Genomics (NASDAQ:TXG) Receives Sell (E+) Rating from Weiss Ratings - Defense World
10x Genomics First Quarter 2025 Earnings: Beats Expectations - simplywall.st
30,005 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Raymond James Financial Inc. - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Q1 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target for 10x Genomics (TXG) Amid Market Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Lowered to $9 by JP Morgan | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain O - GuruFocus
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Conc - GuruFocus
Deutsche Bank Adjusts Price Target on 10x Genomics to $10 From $16, Maintains Hold Rating - marketscreener.com
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain Outlook | TXG Stock News - GuruFocus
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics (NASDAQ:TXG) adds US$65m to market cap in the past 7 days, though investors from five years ago are still down 89% - simplywall.st
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics Reports First Quarter 2025 Financial Results - BioSpace
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - GuruFocus
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance - Benzinga
10x Genomics: Q1 Earnings Snapshot - CTPost
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations - Yahoo Finance
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Announces Workforce Reduction to Cut Costs - TipRanks
10x Genomics Inc Q1 2025 Earnings: EPS of -$0.28 Beats Estimate, Revenue Surges to $154.9 Million - GuruFocus
Earnings Flash (TXG) 10x Genomics Posts Q1 Loss $-0.28 Per Share, vs. FactSet Est of $-0.47 - marketscreener.com
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago - Yahoo Finance
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Feb 28 '25 |
Sale |
10.63 |
7,942 |
84,393 |
871,540 |
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):